Gene Biotherapeutics, Inc.
Gene Biotherapeutics, Inc. (CRXM): 6 pipeline candidates · ~4 mo cash runway · 7 clinical trials. Updated within the last hour.
BioSniper Score
4-factor signal · derived from public data
3.5 months
D/E -1.33 · 0% dilution
Lead: Approved
6 candidates
N/A
N/A
A transparent, data-derived signal for Gene Biotherapeutics, Inc.across cash runway, pipeline maturity & breadth, catalyst momentum and clinical/regulatory footprint. Each factor traces to tracked public filings — not an investment recommendation.
Key Financials
Market Cap
—
Cash
$386K
Quarterly Burn
$338K
Runway
3.5 mo
Revenue
—
Cash Runway vs Catalysts
Tracked catalysts land within the current projected cash runway.
Pipeline (6 candidates)
| Drug | Phase |
|---|---|
| a2b543 | Phase 1/Phase 2 |
| a2b694 | Phase 1/Phase 2 |
| elamipretide | Phase 3 |
| excellagen | Approved |
| gene therapy | Phase 1/Phase 2 |
| generx | Phase 3 |
Frequently asked questions
How many drug candidates are in Gene Biotherapeutics, Inc.'s pipeline?
Gene Biotherapeutics, Inc. (CRXM) has 6 pipeline candidates tracked by BioSniper across SEC filings and clinical trial registrations.
What is Gene Biotherapeutics, Inc.'s lead drug candidate?
Gene Biotherapeutics, Inc.'s most advanced tracked candidate is a2b543 (Phase 1/Phase 2) for Solid Tumor, Adult.
What is Gene Biotherapeutics, Inc.'s cash runway?
Based on its most recent reported cash balance and quarterly burn rate, Gene Biotherapeutics, Inc. has approximately 3.5 months of cash runway.
Who is the CEO of Gene Biotherapeutics, Inc.?
Sorrento Valley Road is the chief executive officer of Gene Biotherapeutics, Inc. (CRXM).
Get the full picture on Gene Biotherapeutics, Inc.
Deep pipeline analysis, financial trends, AI-powered investment signals, and real-time catalyst alerts.